The full FDA clinical hold formally halts all tests of Aardvark Therapeutics’ drug for Prader-Willi syndrome, a rare inherited metabolic disorder that leads to excessive eating. Earlier this year, Aardvark voluntarily paused all tests of its small molecule after a cardiovascular problem emerged in a healthy volunteer.
The post Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug appeared first on MedCity News.
